Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): Primary analysis

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2025
This article has no abstract
Epistemonikos ID: 943386a639702a775ed442d9fb5f24c707580bcb
First added on: Jul 05, 2025